1 / 23

PHAR 751 Pharmacogenomics

PHAR 751 Pharmacogenomics. Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org. PK: p-gp & sex, racial background. ∆ Males ■ Females ○ African Americans ▼European Americans.  No difference between groups. Genotype vs. Phenotype: exon 26.

edolie
Télécharger la présentation

PHAR 751 Pharmacogenomics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org

  2. PK: p-gp & sex, racial background ∆ Males ■ Females ○ African Americans ▼European Americans  No difference between groups

  3. Genotype vs. Phenotype: exon 26 MDR1 exon 26, C3435T □ CT ■ CC ○ TT P=0.036 CC vs. TT 180 mg fexofenadine po

  4. Genotype vs. Phenotype: exon 21 MDR1 exon 21, G2677T □ GT ■ GG ○ TT P= 0.054 GG vs. TT

  5. Genotype vs. Phenotype MDR1*1 or MDR1*2 alleles □ *1*2 ■ *1*1 ○ *2*2

  6. Study conclusions • Multiple SNPs present in the human MDR1 gene • Polymorphism alters p-gp activity • Genetic variation differs d/t racial background

  7. Another Fexofenadine, p-gp study • Is the disposition of fexofenadine in humans affected by polymorphisms of MDR1? • TT genotype vs. CC genotype Drescher, et al. MDR1 gene polymorphisms and disposition of the p-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-534.

  8. CC vs. TT genotype ■ CC ○ TT Fexofenadine concentration vs. Time Drescher, et al. MDR1 gene polymorphisms and disposition of the p-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-534.

  9. GG vs. TT phenotype ■ GG ○ TT  Not significant Fexofenadine concentration vs. Time Drescher, et al. MDR1 gene polymorphisms and disposition of the p-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-534.

  10. Different conclusions? • This study: NS difference in PK of fexofenadine • Known: fexofenadine is a p-gp substrate • Unknown: lack of association btwn PK and polymorphism

  11. Polymorphisms: Enzymes • Frequently polymorphic • Phenotypic consequence • Leads to inter-individual variability in drug response? • Other factors: molecular basis, expression of other drug-metabolizing enzymes, concurrent medications or illnesses

  12. Consequences of enzyme polymorphisms: Drug toxicities • Thiopurine methyltransferase-deficiency • Hematopoietic toxicity when treated w/ standard doses of azathioprine or mercaptopurine • Slow acetylator phenotype • Hydralazine-induced lupus • Isoniazid-induced neuropathies • Dye-associated bladder cancer • Sulfonamide-induced hypersensitivity rxns

  13. NAT2 polymorphism: Isoniazid Slow acetylator vs. Fast acetylator

  14. N-acetyltransferase (NAT2) polymorphism • Europe, North America: 40 – 70% slow acetylators (SA) • Pacific Asian: 10 – 30% SA • Egyptian and Moroccan: 80 – 90% SA • Canadian Eskimo: 5% SA

  15. Acebutolol (a) Isoniazid Aminobenzoic Acid Nitrazepama Aminogluthethimide Phenelzine Aminosalicylic Acid Procainamide Amrinone Sulfadiazine Caffeine (a) Sulfamerazine Clonazepam Sulfamethazine Dapsone Sulfapyridine Hydralazine Sulfasalazine Agents Undergoing Polymorphic N-acetylation (a) =Requires metabolism before N-acetylation

  16. CYP2C polymorphisms

  17. Consequences of enzyme polymorphisms • ↑ CYP1A activity + slow acetylation = ↓ myelosuppression from active metabolites of amonafide • ↓ drug-metabolizing enzyme  ↓ pro-drug activation • CYP2D6, opioid analgesics

  18. PK: Ethnic differences • Unlikely: • No gut or hepatic first-pass effect • Low plasma protein-binding (<70-80%) • No/minimal hepatic metabolism • No/minimal renal tubular secretion • Likely: • Gut or hepatic metabolism • High plasma protein-binding • Hepatic metabolism as major route

  19. Chinese vs. Caucasians Higher metabolism Propranolol Morphine No difference Triazolam Cerivastatin Lower metabolism Desipramine Alprazolam Diazepam Omeprazole Nifedipine Codeine Ethnic differences: hepatic metabolism

  20. African descent vs. Caucasians Higher metabolism Propranolol Lower metabolism Nifedipine Methyprednisolone Phenytoin No difference Metoprolol/labetolol Albuterol Terbutaline Trimazosin Procainamide Etoposide Ethnic differences: hepatic metabolism

  21. Ethnic variations • Passive absorption, filtration at the glomerulus, and passive tubular reabsorption will not differ between ethnic groups • For many drugs, PK prediction is difficult

  22. Genetic testing • Carrier testing • Diagnostic testing • Newborn screening • Pharmacogenetic testing

  23. Clinical Relevance • Small numbers of patients • Availability of genotyping and phenotyping tools • Genetic testing • Predicting • Drug interactions • Therapeutic window • In practice…

More Related